HELLA GmbH & Co. KGaA

  • WKN: A13SX2
  • ISIN: DE000A13SX22
  • Land: Deutschland

Nachricht vom 23.09.2021 | 11:06

HELLA GmbH & Co. KGaA lowers sales and earnings forecast for the current fiscal year due to significantly reduced market expectations for global vehicle production

HELLA GmbH & Co. KGaA / Key word(s): Change in Forecast
HELLA GmbH & Co. KGaA lowers sales and earnings forecast for the current fiscal year due to significantly reduced market expectations for global vehicle production

23-Sep-2021 / 11:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


HELLA GmbH & Co. KGaA lowers sales and earnings forecast for the current fiscal year due to significantly reduced market expectations for global vehicle production

- Significant decline in global vehicle production forecast as a result of further worsening market bottlenecks

- HELLA lowers forecast for sales and profit margin

Lippstadt, 23 September 2021. HELLA GmbH & Co. KGaA has lowered its sales and earnings forecast for the current fiscal year against the backdrop of significantly reduced market expectations as a result of further worsening supply bottlenecks, particularly for electronic components. For the current fiscal year 2021/2022, the company now expects sales adjusted for currency and portfolio effects in the range of around 6.0 to 6.5 billion euros (previously: around 6.6 to 6.9 billion euros) and an EBIT margin adjusted for structural measures and portfolio effects of around 5 to 7 percent (previously: around 8 percent).

The adjustment of the company's outlook is made against the backdrop of the latest market forecasts by renowned industry service providers and market analysts, according to which global vehicle production will decline by more than eight percent in the current fiscal year 2021/2022 (1 June 2021 to 31 May 2022). In July 2021, growth of almost four percent was still expected.


23-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021